1. Scrip
  2. >>R&D

Wave’s Huntington Drugs Wipe Out As Trials Run Aground

WVE-120102 And WVE-120101 Fail To Show Benefit

 
• By Alaric DeArment

The company now turns to its next-generation Huntington drug, WVE-003.

Amazing, perfect wave - Image
Wave is moving on to next-generation drug WVE-003 after its first-generation Huntington drugs failed. • Source: Shutterstock

WAVE Life Sciences Ltd. is banking on its next-generation asset for Huntington disease (HD) after the failure of a clinical trial program of two earlier-generation drugs, which itself closely follows Roche Holding AG’s discontinuation of its own HD trial. Wave is hoping that the new drug’s improved preclinical pharmacology will raise the odds of success.

The Cambridge, MA-based company announced 29 March that data from the Phase Ib/IIa PRECISION-HD2 study of WVE-120102 and the PRECISION-HD1 study of WVE-120101 did not show statistically significant efficacy in patients with HD and therefore did not support continued development. Consequently, the company is planning to pursue its next-generation HD drug, WVE-003

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.